ReviewThe Journal of molecular diagnostics : JMD2010
Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.
Review in The Journal of molecular diagnostics : JMD, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 51 citations in OpenAlex.
- Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.Frontiers in medicine · 2026Review
- Research progress on molecular biomarkers of acute myeloid leukemia.Frontiers in oncology · 2023Review
- Article
- Biomarkers in Acute Myeloid Leukemia: Leveraging Next Generation Sequencing Data for Optimal Therapeutic Strategies.Frontiers in oncology · 2021Review
- Genetic Characterization and Risk Stratification of Acute Myeloid Leukemia.Cancer management and research · 2020Review
- A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.Leukemia & lymphoma · 2018Article
- Discriminate the response of Acute Myeloid Leukemia patients to treatment by using proteomics data and Answer Set Programming.BMC bioinformatics · 2018Article
- Article
- Unravelling the genomic landscape of leukemia using NGS techniques: the challenge remains.Blood research · 2017Article
- Evolution-informed modeling improves outcome prediction for cancers.Evolutionary applications · 2017Article
- Epigenetic dysregulation ofJournal of Cancer · 2017Article
- Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.International journal of clinical and experimental pathology · 2015Article
- Minimal residual disease in acute myeloid leukaemia.Nature reviews. Clinical oncology · 2013Review
- Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations.Molecular diagnosis & therapy · 2012Review
- Chromosomal instability and cancer: a complex relationship with therapeutic potential.The Journal of clinical investigation · 2012Review
- Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Management of patients with acute myeloid leukemia relies on genetic tests that inform diagnosis and prognosis, predict response to therapy, and measure minimal residual disease. The value of genetics is reinforced in the revised 2008 World Health Organization acute myeloid leukemia classification scheme. The various analytic procedures-karyotype, fluorescence in situ hybridization, reverse transcription polymerase chain reaction, DNA sequencing, and microarray technology-each have advantages in certain clinical settings, and understanding their relative merits assists in specimen allocation and in effective utilization of health care resources. Karyotype and array technology represent genome-wide screens, whereas the other methods target specific prognostic features such as t(15;17) PML-RARA, t(8;21) RUNX1-RUNX1T1, inv(16) CBFB-MYH11, 11q23 MLL rearrangement, FLT3 internal tandem duplication, or NPM1 mutation. New biomarkers and pharmacogenetic tests are emerging. The pathologist's expertise is critical in 1) consulting with clinicians about test selection as well as specimen collection and handling; 2) allocating tissue for immediate testing and preserving the remaining specimen for any downstream testing that is indicated once morphology and other pertinent test results are known; 3) performing tests that maximize outcome based on the strengths and limitations of each assay in each available specimen type; and 4) interpreting and conveying results to the rest of the health care team in a format that facilitates clinical management. Acute myeloid leukemia leads the way for modern molecular medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.